H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Axsome Therapeutics (AXSM) today and set a price target of $200.00. The company’s shares closed last Friday at $55.02.
According to TipRanks.com, Selvaraju has 0 stars on 0-5 star ranking scale with an average return of -12.7% and a 23.0% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Taro Pharmaceutical Industries, Biospecifics Technologies, and Springworks Therapeutics.
Axsome Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $157.33, implying a 183.2% upside from current levels. In a report issued on March 30, BTIG also maintained a Buy rating on the stock with a $107.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $109.95 and a one-year low of $13.25. Currently, Axsome Therapeutics has an average volume of 862K.
Based on the recent corporate insider activity of 7 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of AXSM in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Axsome Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies for the management of central nervous system disorders. Its product candidates include AXS-02 and AXS-06 which are developing for multiple indications. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.
